ARIA Super News !Bristol-Myers Squibb Signs NF-kB License Agreement - 500 Beiträge pro Seite

[reichinrente]

Hi Bio-Freunde,
gute Nachrichten - Endlich die erste Lizenzvereinbarung mit einem Big Pharma! Das spült Geld in die Kassen und zieht weitere Partner an! Heute + 30 %
Es hat sich mal wieder ausgezahlt, nicht auf das unqualifizierte Gebashe einiger Shorties zu hören - aber da muß jeder für sich selber entscheiden...

RiR

Bristol-Myers Squibb Signs NF-kB License Agreement With ARIAD

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 6, 2002--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced a non-exclusive worldwide license agreement with Bristol-Myers Squibb Company (NYSE:BMY) that grants Bristol-Myers Squibb the right to conduct pharmaceutical research and development covered by ARIAD`s pioneering NF-(kappa)B patents, retroactive to September 8, 1998. Bristol-Myers Squibb will pay ARIAD an up-front license fee and annual license fees, as well as product development and commercialization milestones and royalties based on sales of products discovered using ARIAD`s patented NF-(kappa)B drug-discovery methods. Financial terms were not disclosed because ARIAD is actively pursuing agreements with additional licensees.

NF-(kappa)B can generally be thought of as a "biological switch" that can be turned off in cells to treat various disease conditions, such as inflammation, cancer, and osteoporosis. The licensed patents are part of ARIAD`s NF-(kappa)B patent portfolio awarded to the Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, and Harvard University. ARIAD has an exclusive license to these patents.

"Our agreement with Bristol-Myers Squibb is the first license of our NF-(kappa)B patent estate and covers an important area of R&D for Bristol. There are many additional potential licensees of our NF-(kappa)B patents and we are committed to creating value for the team of distinguished inventors, their institutions, and our stockholders through a broad licensing program for our NF-(kappa)B patents," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD.

ARIAD is engaged in the discovery and development of breakthrough medicines that regulate cell signaling with small molecules. The Company is developing a comprehensive approach to the treatment of cancer and blood diseases and has seven product candidates in development. ARIAD also has an exclusive license to pioneering technology and patents related to the discovery, development and use of drugs that regulate NF-(kappa)B cell-signaling activity, which has been implicated in many major diseases.

Additional information about ARIAD and its family of NF-(kappa)B patents can be found on the web at http://www.ariad.com

[gholzbauer]

Es geschehen noch Zeichen und Wunder.
Wenn jetzt zusätzlich LLY mit ein paar hundert Mio $ rüberkommt ...

[reichinrente]

Hallo Biotech-Gemeinde,
bei ARIA ist was im "Bush".

-> Heute + 13 % im plus ohne News.
-> In FFm wurde deutlich darunter getaxt.
-> Nachbörslich steigende Kurse bei ungewöhnlich hohem Volumen !!

Abgesehen von dem kurzfristigen Zock ist Ariad aufgrund seines Geschäftsmodells und der Produktpipline ohnehin ein sehr interessantes Investment.

Morgen wissen wir mehr - schaut mal rein!

Rich!

[reichinrente]

Hallo Ariad-Freunde,
heute gab`s wieder äußerst erfreuliche News von Ariad !
AP23464 hat sich den Studien gegen Blutkrebs 10-fach wirksamer als der Blockbuster Gleevec von Novartis !!!!!herausgestellt und geht jetzt in die nächste klinische Phase.

Normalerweise hätte diese Nachricht für mindestens 30 - 50 % Kursteigeung gut sein müssen, aber "Jemand" hat den Deckel drauf (Novartis ?) .
Ariad hat noch viele andere potenielle Produkte in der Pipline und ist z.Zt. nur mit lächerlichen 147 mio $ bewertet. Dennoch, dieses Unternehmen wird garantiert früher oder später seinen zu seinem realen Marktwert kommen.

Grüsse
Rich

ARIAD Reports Studies Profiling Potency and Activity of Its Molecularly Targeted Product for Blood Cancer
Monday July 7, 7:30 am ET
Highlighted at UK Cancer Research International Conference


CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 7, 2003-- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - News) today announced, for the first time, results of pre-clinical studies demonstrating the potency and activity of AP23464, its product candidate to treat life-threatening forms of blood cancer: AP23464 is over 10-fold more potent than imatinib (Gleevec(TM)), the leading product for chronic myeloid leukemia (CML), in blocking the activity of the key cancer-causing protein responsible for Gleevec`s efficacy.
ADVERTISEMENT


Furthermore, unlike Gleevec, AP23464 is designed to block additional leukemia therapeutic targets that become increasingly important in patients who no longer respond to Gleevec - an outcome that occurs in approximately 75% of advanced-stage CML patients treated with Gleevec for two years. In spite of these limitations, sales of Gleevec are estimated to reach approximately $1 billion in 2003.

Based on its targeting of oncogenic proteins, AP23464 may provide a compelling alternative to Gleevec - both for Gleevec-resistant patients and as primary therapy for certain forms of leukemia.

"The success of Gleevec, described as a `magic cancer bullet,` highlights the importance of selecting the right therapeutic targets for new cancer therapies. We are focused on development of our molecularly targeted drug for blood cancer to be ARIAD`s next product candidate to enter clinical trials," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD.

The malignant transformation in bone marrow cells that leads to certain forms of leukemia is dependent on the activity the Abl protein. Dr. David Baltimore`s research group discovered the cancer-causing properties of the Abl protein in the mid-1980`s. Dr. Baltimore is one of ARIAD`s founding scientific advisors. Recent clinical studies have found that genetic variants of Abl develop during Gleevec treatment. While Gleevec does not affect these variant proteins or the Src protein, an important cell-signaling partner of Abl, AP23464 is designed to block these proteins.

[reichinrente]

Hallo Aria-Freunde,
heute wieder extrem gute Nachrichten für ARIAD (Erweitertes Einsatzfeld von AP23841 für Knochenkrebs - Millardenmarkt !!!!) wieder ein potentielles Konkurenzprodukt (zometa) für Novartis, und wieder ist der Kurs gedeckelt..
Das gibt`s doch nicht! Bei jeder anderen Klitsche wäre heute der Kurs explodiert.
Obacht, da läuft garantiert noch was ! Schade, dass dieses Unternehmen so unter Wert gehandelt wird..

rich
ARIAD Research Highlights Beneficial Profile of Its Promising Product to Treat Cancer That Has Spread to Bone
Monday July 14, 7:31 am ET
Lead Story in American Association for Cancer Research Press Release


CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 14, 2003-- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - News) announced, for the first time on Saturday at the American Association for Cancer Research press briefing on the efficacy of novel cancer treatments, results of pre-clinical studies demonstrating the potential therapeutic benefits of its product candidate to treat cancer that has spread to bone.
ADVERTISEMENT


AP23841 combines, in a single small-molecule drug, effective blockade of both tumor growth and bone destruction - the two processes that need to be controlled to treat the grave clinical consequences of bone metastases.

Of the more than 5000 abstracts that were submitted for presentation to the 94th annual meeting of the AACR, three were featured in its press release entitled "New generation of treatments show promise for cancer patients: Studies show combined therapies, new targets effective in fighting disease." The lead story in the AACR release was ARIAD`s product candidate to treat cancer in bone.

Even though none of the available therapies for bone metastases directly affects both tumor growth and bone destruction, sales of zoledronic acid (Zometa®), the leading bisphosphonate used for this indication, are estimated to reach approximately $1 billion in 2003.

"The development of a novel therapy for bone metastases that acts directly and potently on both tumor growth and bone destruction should be highly desirable from a clinical and mechanistic standpoint and should have potential added benefit over existing drugs used to treat this disease," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD.

Approximately 750,000 cancer patients worldwide will die this year with bone metastases. Some of the most common solid tumors - breast, prostate, lung and kidney cancer - commonly spread to bone, resulting in severe bone pain and pathological fractures due to increased bone fragility.

AP23841 is similar to ARIAD`s lead cancer product, AP23573. Both product candidates inhibit the activity of a protein known as mTOR, which results in the starvation of cancer cells. However, AP23841 is designed to selectively concentrate in bone, which should deliver a more potent therapeutic effect to cancer cells that have migrated to bone. AP23841 also blocks the activity of bone cells responsible for bone destruction. Stopping bone destruction impedes the release of growth factors that attract cancer cells to bone and stimulate their proliferation in bone.

Saturday`s press release issued by the AACR is available at the AACR web site (http://www.aacr.org/1132ab.asp), as is the abstract by Metcalf, C., et al, "A novel, bone-targeted mTOR inhibitor that decreases both tumor proliferation and bone breakdown for the treatment of cancer," (http://www.aacr.org/2003AM/2003AM.asp).

ARIAD is engaged in the discovery and development of breakthrough medicines that regulate cell signaling with small molecules. The Company is developing a comprehensive approach to the treatment of cancer and is primarily focused on a series of product candidates for targeted oncology indications. ARIAD also has an exclusive license to pioneering technology and patents related to the discovery, development and use of drugs that regulate NF-(kappa)B cell-signaling activity, which has been implicated in many major diseases.

Additional information about ARIAD can be found on the web at http://www.ariad.com